Targeting Breast Cancer Using Adoptive Cell Transfer Incorporating Vaccination

Grant number: CCR16376637 | Funding period: 2017 - 2020

Completed

Abstract

Chimeric antigen receptor (CAR) T cell therapy is a novel form of adoptive cellular therapy and has recently generated remarkable effects in patients with hematological cancers. However, the success against solid cancers has been modest. Here, I present a major advancement in CAR T therapy that eradicated large established breast cancers in immunocompetent mice. The approach involves adoptive cell transfer incorporating vaccination (ACTIV) therapy. Transferred cells comprise dual-specific T lymphocytes expressing a CAR targeting the breast cancer-associated antigen Her2 and T cell receptor (TCR) specific for the strong immunogen, gp100. The vaccine is composed of recombinant oncolytic vaccin..

View full description

Related publications (5)

University of Melbourne Researchers